Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Immunol. 2013 Dec 9;192(1):59–72. doi: 10.4049/jimmunol.1301513

Figure 6. Inhibition of the JAK/STAT Pathway Suppresses PLP-induced Relapsing-Remitting EAE Disease.

Figure 6

(A). SJL/J mice were immunized with PLP139-151 peptide (200 μg) emulsified in CFA containing M. tuberculosis. Vehicle Control (0.1% DMSO) (n=4) or AZD1480 (25 mg/kg) (n=5) was administrated by oral gavage daily starting at day 7 for 10 days, and then a second treatment at day 60 for 10 days. Mean ± S.D. of EAE clinical scores. (B). Mice were perfused, spinal cord removed, and protein extracts from PLP139-151-immunized Vehicle Control or AZD1480 treated mice at day 75 were immunoblotted with the indicated antibodies, and (C) mRNA was analyzed by qRT-PCR. *p<0.05 and **p<0.001.